Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.
The revisions balance a growing understanding of gender identity disorders and societal views with the need to retain conditions that benefit from intervention and the removal of which would hamper patients’ ability to receive medical treatment.